Christmas 2020 roundup from the TherapeutAix team

As 2020 draws to a close, the team at TheraeutAix has been looking back and reflecting on the last 12 months. Here’s a recap. A pandemic that changed a lot Let’s start with the obvious. The coronavirus pandemic challenged how we engaged with colleagues, conferences and in networking. We enjoyed our only in person meeting […]
Challenges in inhaled drug therapy

In the first blog of this series1, we highlighted that, despite the potential advantages, there appear to be only a few opportunities pursuing the inhaled route of delivery in IPF. Our perception is that there is a “double whammy” here – a general nervousness in the Pharma and Investor community regarding inhalation per se and […]
Drug Development in IPF

Drug development in Idiopathic Pulmonary Fibrosis (IPF) remains challenging. The pharmacological properties of the two approved drugs, pirfenidone and nintedanib, need to be considered when selecting and developing new drug candidates. We discuss the challenges and opportunities in our new review in Drug Discovery Today. We probably don’t need to highlight the fact that despite […]